Granulocyte colony-stimulating factors for primary prophylaxis of febrile neutropenia: Cost-effectiveness analysis and impact on survival outcomes

Introduction. The development of febrile neutropenia (FN) is associated with high mortality and significant healthcare costs. Currently, granulocyte colony-stimulating factors (G-CSF) are recommended for patients with at least one clinical risk factor for FN in chemotherapy (CT) regimens with an intermediate risk of complications (10–20%). The question remains open as to how optimally FN prevention is carried out and how the use of G-CSF affects the budget of a medical institution in the treatment of patients with an intermediate risk of complications.

Aim. To assess the impact of primary FN prevention on the costs of a medical institution and on survival rates in patients undergoing intermediate-risk CT regimens.

Materials and methods. A retrospective analysis of 252 patient medical records was conducted (average age 66.8 years; 52% women, 48% men). A model was developed to assess the impact on the budget of a medical institution, taking into account direct medical costs for prevention, laboratory and instrumental studies, and treatment of episodes of neutropenic complications, as well as patient death by the time of analysis.

Results. Direct costs per patient for FN prevention amounted to 53,095.26 RUB and were 6% higher (3,212.16 RUB) compared to the group without prevention. Primary FN prevention led to a reduction in episodes of neutropenia, with a risk difference in the FN prevention group -26.1 (95% CI -35.6; -14.1), p < 0.001. As a result, one-year survival in the neutropenia prevention group was statistically significantly lower at 66.1% (41 out of 62), and costs per patient were 33% lower (19,840.44 RUB) compared to the group without prevention.

Conclusion. The prescription of primary prevention using G-CSF is associated with a reduction in the frequency of neutropenia development and an improvement in both immediate and long-term outcomes, positively affecting the institution’s budget.

1. Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, DeLeon A et al. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy. J Manag Care Spec Pharm. 2018;24(10):976–984. https://doi.org/10.18553/jmcp.2018.17447.

2. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087. https://doi.org/10.1136/bmj.m4087.

3. Liutkauskiene S, Grizas S, Jureniene K, Suipyte J, Statnickaite A, Juozaityte E. Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer. 2018;18(1):453. https://doi.org/10.1186/s12885-018-4365-y.

4. Denduluri N, Patt DA, Wang Y, Bhor M, Li X, Favret AM et al. Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices. J Natl Compr Canc Netw. 2015;13(11):1383–1393. https://doi.org/10.6004/jnccn.2015.0166.

5. Sakaeva DD, Borisov KE, Bulavina IS, Kogonia LM, Kurmukov IA, Orlova RV, Shabaeva MM. Febrile Neutropenia. RUSSCO Practice Guidelines, Part 2. Malignant Tumors. 2024;14(3s2):61–70. (In Russ.) Available at: https://rosoncoweb.ru/standarts/RUSSCO/2024/2024-2-04.pdf.

6. Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P et al. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw. 2020;1:1–4. https://doi.org/10.6004/jnccn.2020.7610.

7. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129–146. https://doi.org/10.1016/j.critrevonc.2004.01.001.

8. Wang W, Li E, Campbell K, McBride A, D’Amato S. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework. JCO Oncol Pract. 2021;17(8):e1139–e1149. https://doi.org/10.1200/OP.20.00994.

9. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213–226. https://doi.org/10.1002/sim.4780040211.

10. Zheleznyakova IA, Plakhotnik OS, Rumyantseva EI, Sidorova EA, Vakhrusheva TS, Yakina AS et al. Changes in diagnosis-related group payment model in the Russian Federation in 2025. Medical Technologies. Assessment and Choice. 2025;47(2):18–30. (In Russ.) https://doi.org/10.17116/medtech20254702118.

11. Rumyantseva EI, Zheleznyakova IA, Plakhotnik OS, Nikitin FS, Vakhrusheva TS, Aviaeva TS et al. Changes in diagnosis-related group payment model in the Russian Federation in 2024. Medical Technologies. Assessment and Choice. 2024;46(2):10–21. (In Russ.) https://doi.org/10.17116/medtech20244602110.

12. Vanderpuye-Orgle J, Sexton Ward A, Huber C, Kamson C, Jena AB. Estimating the social value of G-CSF therapies in the United States. Am J Manag Care. 2016;22(10):e343–e349. Available at: https://www.ajmc.com/view/estimating-the-social-value-of-g-csf-therapiesin-the-united-states.

13. Baig H, Somlo B, Eisen M, Stryker S, Bensink M, Morrow PK. Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. J Oncol Pharm Pract. 2019;25(7):1576–1585. https://doi.org/10.1177/1078155218799859.

14. Weycker D, Doroff R, Hanau A, Bowers C, Belani R, Chandler D et al. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: A retrospective observational study. BMC Cancer. 2019;19(1):792. https://doi.org/10.1186/s12885-019-6010-9.

15. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–3167. https://doi.org/10.1200/JCO.2006.08.8823.

16. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214. https://doi.org/10.1200/JCO.2005.05.645.

17. Pérez Velasco R. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia. J Oncol Pharm Pract. 2011;17(3):225–232. https://doi.org/10.1177/1078155210374129.

18. Snegovoy AV, Kononenko IB, Sorokina IV, Berezina AM, Prosianikova ON. The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results. Journal of Modern Oncology. 2023;25(3):378–384. (In Russ.) https://doi.org/10.26442/18151434.2023.3.202452.

19. Krivorotko PV, Burdaeva ON, Nechaeva MN, Frolova MA, Kopp MV, Abrosimova AA, Ivanov RA. Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy. Journal of Modern Oncology. 2015;17(2):45–52. (In Russ.) Available at: https://modernonco.orscience.ru/1815-1434/article/view/27010.

20. Snegovoy AV, Kononenko IB, Radiukova IM, Orlova SA, Sultanbaev AV, Dubovichenko DM et al. Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study. Journal of Modern Oncology. 2024;26(2): 159–171. (In Russ.) https://doi.org/10.26442/18151434.2024.2.202829.

21. Gromova GA. Prevention and treatment of neutropenia in routine clinical practice. How to improve the quality of cancer care and reduce treatment costs? Opuholi Zenskoj Reproduktivnoj Sistemy. 2023;19(2):69–81. (In Russ.) https://doi.org/10.17650/1994-4098-2023-19-2-69-81.

22. Zhuravleva MV, Kokushkin KA, Luchinin EA, Luchinina EV, Kameneva TR, Kuznetsova EV et al. Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(4):537–548. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.220.

23. Litovkin AV, Parfenov YuA, Parfenov SA, Sapozhnikov KV. Forms of palliative care for those older adults with cancer. Modern Problems of Science and Education. 2017;(4):58. (In Russ.) Available at: https://www.elibrary.ru/cgskwk.

24. Ashour АZ, Litovkin VA, Belov VG, Parfyonov UA, Parfyonov SA, Spicina AA et al. Analysis of health and social needs of cancer patients of older age groups in palliative care. Modern Problems of Science and Education. 2015;(5):335. (In Russ.) Available at: https://www.elibrary.ru/yticsb.

25. Li E, Mezzio DJ, Campbell D, Campbell K, Lyman GH. P Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis. JCO Oncol Pract. 2021;17(8):e1235–e1245. https://doi.org/10.1200/OP.20.01047.

26. Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16(6):720–735. https://doi.org/10.3111/13696998.2013.782034.

27. Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J. Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. Clin Lung Cancer. 2018;19(2):e163–e169. https://doi.org/10.1016/j.cllc.2017.10.013.

28. Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10. J Clin Oncol. 2008;26(31):5052–5059. https://doi.org/10.1200/JCO.2007.12.6094.

29. Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: A systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23(11):3131–3140. https://doi.org/10.1007/s00520-015-2686-9.

30. Ramsden K, Laskin J, Ho C. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment. Clin Oncol (R Coll Radiol). 2015;27(7):394–400. https://doi.org/10.1016/j.clon.2015.03.001.